- Trials with a EudraCT protocol (4)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
4 result(s) found for: Amyloid plaque.
Displaying page 1 of 1.
EudraCT Number: 2014-002855-25 | Sponsor Protocol Number: EIP-VX00-745-302 | Start Date*: 2015-03-11 | |||||||||||
Sponsor Name:EIP Pharma, LLC | |||||||||||||
Full Title: A Clinical Study of Two Doses of a Selective p38 MAP Kinase Inhibitor, VX-745, to Evaluate the Effects of 12-Week Oral Twice-Daily Dosing on Amyloid Plaque Load as Assessed by Quantitative Dynamic ... | |||||||||||||
Medical condition: Alzheimer’s disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-001671-14 | Sponsor Protocol Number: 221AD305 | Start Date*: 2022-11-18 | |||||||||||
Sponsor Name:Biogen Idec Research Limited | |||||||||||||
Full Title: A Phase 3b/4 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Verify the Clinical Benefit of Aducanumab (BIIB037) in Participants with Alzheimer's Disease | |||||||||||||
Medical condition: Alzheimer's Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Prematurely Ended) FI (Prematurely Ended) PT (Prematurely Ended) BE (Completed) IT (Prematurely Ended) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-004583-11 | Sponsor Protocol Number: Local/2015/DR-01 | Start Date*: 2016-08-09 |
Sponsor Name:CHU de Nîmes | ||
Full Title: Evaluation du Florbetaben comme marqueur de la plaque amyloïde chez les patients âgés présentant une hémosidérose superficielle focale ou disséminée : comparaison avec des patients atteints de mala... | ||
Medical condition: Cerebral amyloid angiopathy | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2010-021155-11 | Sponsor Protocol Number: H8A-MC-LZAO | Start Date*: 2010-11-29 | |||||||||||
Sponsor Name:Eli Lilly and Company | |||||||||||||
Full Title: Continued Efficacy and Safety Monitoring of Solanezumab, an Anti-Amyloid β Antibody in Patients with Alzheimer’s Disease | |||||||||||||
Medical condition: Alzheimer's disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) ES (Completed) IT (Completed) SE (Prematurely Ended) GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
